Sravani Gundarlapalli

Researcher

UAMS

Last publication 2026 Last refreshed 2026-05-16

faculty

5 h-index 21 pubs 69 cited

Research Areas

Links

Research Group

OverviewAI-generated summary

Sravani Gundarlapalli's research focuses on multiple myeloma, a hematologic malignancy. Her work investigates treatment strategies and outcomes for patients, particularly those with relapsed or refractory disease. This includes studies on the efficacy of salvage autologous stem cell transplantation in patients who have become resistant to therapies like daratumumab. Gundarlapalli also examines the feasibility of outpatient stem cell transplantation and identifies risk factors associated with hospital admission. Another area of her research involves the role of minimal residual disease (MRD) in predicting disease progression and risk in multiple myeloma patients, including the significance of persistent bone marrow MRD after initial transplantation. Her publications also address the corneal toxicity associated with specific treatments like belantamab mafodotin. Gundarlapalli has an h-index of 5 and has published 21 papers with 67 citations, collaborating extensively with researchers at the University of Arkansas for Medical Sciences, including Nishanth Thalambedu, Munawwar Hussain, Sharmilan Thanendrarajan, and Guido Tricot.

Metrics

h-index: 5
Publications: 21
Citations: 69

Selected Publications

Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)

DOI OpenAlex
Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (2022)

DOI OpenAlex
Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant (2022)

DOI OpenAlex
MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022)

DOI OpenAlex
Corneal toxicity with belantamab mafodotin: Multi‐institutional <scp>real‐life</scp> experience (2022)

14 citations DOI OpenAlex
Updates in the Management of Multiple Myeloma from the American Society of Hematology Meeting 2021 (2022)

1 citation DOI OpenAlex
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience (2022)

6 citations DOI OpenAlex
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022)

13 citations DOI OpenAlex
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma (2022)

5 citations DOI OpenAlex
Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance (2021)

1 citation DOI OpenAlex
Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials (2021)

2 citations DOI OpenAlex
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma (2021)

14 citations DOI OpenAlex
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status (2021)

3 citations DOI OpenAlex
Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM). (2021)

3 citations DOI OpenAlex
Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma (2021)

4 citations DOI OpenAlex